RBC Capital Sticks to Its Hold Rating for Avid Bioservices (CDMO)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2025
0mins
Should l Buy ?
Source: Business Insider
Analyst Rating and Price Target: RBC Capital analyst Sean Dodge has maintained a Hold rating on Avid Bioservices with a price target of $12.50, while the stock closed at $12.38 recently.
Insider Activity and Sentiment: Corporate insider sentiment for Avid Bioservices is negative, with an increase in insiders selling shares, including a significant sale by the CEO, indicating potential concerns about the company's performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
